Health Care/Hospital
NUS scientists discover novel approach to rejuvenate aged egg cells
Groundbreaking findings provide a proof-of-concept development of a
non-invasive cell-based method to improve the quality of eggs from older
females for IVF
SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Researchers from the Mechanobiology
Institute
2024-09-19 18:28
1727
MGI Tech partners with Dasa to enhance health diagnosis with genetic sequencing in Brazil
New technologies will contribute to performing genetic tests to diagnose cancers, rare diseases and other diseases with greater precision, advancing personalized medicine in the country SÃO PAULO, Brazil, Sept. 18, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building ...
2024-09-19 11:05
1265
Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC
SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocell...
2024-09-19 09:00
4419
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI
* ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) and has progressed through Phase IIa clinical testing. * Preliminary results from this 12-week study demonstrated that ISM001-055 possesses a favorable safety profile and dos...
2024-09-18 21:30
1094
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress
BARCELONA, Spain, Sept. 18, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and rese...
2024-09-18 18:18
1483
TVM Capital Healthcare Announces Investment in Human Longevity, Inc. as Part of its Strategy of Supporting Disease Prevention and Healthy Aging
HLI is one of the most established, global longevity science companies and committed to accelerating living to 100+ years of a healthy, active, and mobile life DUBAI, UAE and RIYADH, Saudi Arabia, Sept. 18, 2024 /PRNewswire/ -- TVM Capital Healthcare, an international healthcare expansion and gr...
2024-09-18 16:00
1542
AI Plus Clinic Tamaplaza Enhances System to Provide Rapid Diagnosis and Peace of Mind with Remote Robots Starting September 2024
YOKOHAMA, Japan, Sept. 18, 2024 /PRNewswire/ -- - New System Integrates AI Technology and Home Healthcare Launched in July 2024 - AI Plus Clinic Tamaplaza, based in Aoba-ku, Yokohama, Kanagawa Prefecture, operating under Kouetsukai Medical Corporation, has announced a new medical system integra...
2024-09-18 14:00
1175
inHearing Technology Inc. Announced the Acquisition of Intricon's Hearing Health Business
ST. PAUL, Minn., Sept. 17, 2024 /PRNewswire/ -- inHearing Technology Inc., a
wholly-owned subsidiary ofHuizhou Jinghao Medical Technology Co., Ltd.,
announced onSeptember 11, 2024, the acquisition of Intricon's Hearing Health
Business.
2024-09-18 10:27
1303
Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI
TAIPEI and SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), , a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that an Investigational New Drug (IND) application for Pidnarulex ...
2024-09-18 10:06
1731
Datasea's New 5G AI Multimodal Agreements Have Already Generated $9.0 Million of 5G-AI Services
Agreements Boost Fiscal 2025 Revenue and Expand Datasea's 5G Application Market Positioning inChina BEIJING, Sept. 17, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based company focused on innovative high-tech acoustics and 5G-Artificial Intelligence ("A...
2024-09-17 21:45
1679
See-Mode Technologies Receives FDA Clearance for Thyroid Ultrasound AI Analysis and Reporting Software
MELBOURNE, Australia, Sept. 17, 2024 /PRNewswire/ -- See-Mode Technologies, a global innovator in AI for ultrasound imaging, today announced the receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their thyroid ultrasound analysis and reporting software. See-Mode's A...
2024-09-17 20:00
1581
Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics
Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with EGFR exon20ins presented at ESMO 2024 * Sunvozertinib demonstrated promising anti-tumor efficacy, regardless of EGFR exon20ins region classification, race, region, baseline brain metastasis, prio...
2024-09-17 15:47
1904
WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024
BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. ...
2024-09-17 00:01
1352
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
BEIJING, Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that Guangzhou Concord Cancer Center ("Guangzhou H...
2024-09-16 20:00
2057
Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment
NANJING, China, Sept. 16, 2024 /PRNewswire/ -- Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products. The study, which focuses on how mutant IDH1 inhibition activates tumor ...
2024-09-16 19:00
1849
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024
* In patients with non-small cell lung cancer (NSCLC) or melanoma who had acquired resistance to checkpoint inhibitors (CPIs), ATN-037 in combination with KEYTRUDA®(pembrolizumab) demonstrated an overall response rate (ORR) of 21.1% and a disease control rate (DCR) of 89.5%. * Data from the...
2024-09-16 18:00
2115
Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024
HONG KONG, Sept. 16, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The prelimina...
2024-09-16 15:35
4526
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through post...
2024-09-15 17:53
3177
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the Phase 2 clinical results of its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or...
2024-09-15 15:10
3009
Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together
PISCATAWAY, N.J., Sept. 14, 2024 /PRNewswire/ -- The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a new era for solid tumor treatment using cell therapy. PM3...
2024-09-15 06:53
2006
Week's Top Stories
Most Reposted
UTP LAUNCHES MALAYSIA'S FIRST BACHELOR IN INTEGRATED ENGINEERING PROGRAMME
[Picked up by 304 media titles]
2024-12-27 13:17
XTransfer and OCBC Jointly Announce Comprehensive Partnership
[Picked up by 266 media titles]
2024-12-23 17:36
CKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
[Picked up by 253 media titles]
2024-12-24 00:06ebm-papst A&NZ Achieves Complete Operational Carbon Neutrality in appropriate Scope 1,2 and 3 criterion in 2023
[Picked up by 245 media titles]
2024-12-25 15:45Huawei Cloud Named a Challenger in Gartner® Magic Quadrant™ for Cloud DBMSs
[Picked up by 239 media titles]
2024-12-27 11:24
